2020
Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas
Deng S, Fan Z, Gong Y, Cheng H, Jin K, Qian Y, Xiao Z, Liu Y, Wang R, Zheng Y, Ni Q, Yu X, Liu C, Luo G. Clinical implication of serum CA125 for the prediction of malignancy in mucinous cystic neoplasms of the pancreas. Experimental And Therapeutic Medicine 2020, 20: 158. PMID: 33093896, PMCID: PMC7571373, DOI: 10.3892/etm.2020.9287.Peer-Reviewed Original ResearchMucinous cystic neoplasmsSerum CA125Carcinoembryonic antigenMalignant changeReceiver Operating CharacteristicCystic neoplasmsCarbohydrate antigenPredictive value of CA125Serum carbohydrate antigenSerum carcinoembryonic antigenPredictive of malignancyValue of CA125CA19-9Predicting malignancyMalignant potentialInvasive groupSerum levelsCA125Grade groupPredictive valueSerumPredictive roleHigh gradeClinical implicationsAntigen
2011
Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma
Gupta D, Gunter MJ, Yang K, Lee S, Zuckerwise L, Chen LM, Goldberg GL, Huang GS. Performance of Serum CA125 as a Prognostic Biomarker in Patients With Uterine Papillary Serous Carcinoma. International Journal Of Gynecological Cancer 2011, 21: 529-534. PMID: 21436701, DOI: 10.1097/igc.0b013e31821091b5.Peer-Reviewed Original ResearchConceptsUterine papillary serous carcinomaPapillary serous carcinomaCA125 levelsLymph node metastasisDisease recurrenceCA125 elevationMetastatic diseaseNode metastasisSerum CA125Serous carcinomaStage III/IV diseaseCox proportional hazards regression modelingProportional hazards regression modelingElevated CA125 levelsPreoperative CA125 levelsLymph node involvementRecurrence-free survivalAdvanced International FederationMultivariate survival analysisUPSC patientsMean followSurgical stagingCA125 measurementNode involvementIndependent predictors
2004
060 Prognostic Value of Serum Ca125 and Marker Half-Life (T½) for Long-Term Progression Free and Overall Survival and Optimal Interval Debulking Surgery (IDS) in Advanced Ovarian Carcinoma. A EORTC-GCG Study
van Luijk I, Coens C, Kobierska A, Colombo N, Favalli G, Lacave A, Nardi M, Pecorelli S, Teodorovic I, van der Burg M. 060 Prognostic Value of Serum Ca125 and Marker Half-Life (T½) for Long-Term Progression Free and Overall Survival and Optimal Interval Debulking Surgery (IDS) in Advanced Ovarian Carcinoma. A EORTC-GCG Study. International Journal Of Gynecological Cancer 2004, 14: 18-19. DOI: 10.1136/ijgc-00009577-200409001-00060.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply